Cara Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 11, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 11, 2025
TVRD$1.41+47.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| · · Year Ended December 31, | |||||||||
| | 2024 | 2023 | 2022 | ||||||
| Revenue: | | | | | | | | | |
| Collaborative revenue | | $2,086 | | $12,936 | | $16,572 | |||
| Commercial supply revenue | | | 640 | | | 5,843 | | | 10,223 |
| License and milestone fees | | | — | | | 910 | | | 15,000 |
| Royalty revenue | | | — | | | 415 | | | 72 |
| Clinical compound revenue | | 84 | | 165 | | — | |||
| Other revenue | | | 4,327 | | | 699 | | | — |
| Total revenue | | 7,137 | | 20,968 | | 41,867 | |||
| Operating expenses: | | | | ||||||
| Cost of goods sold | | | 620 | | | 6,174 | | | 7,266 |
| Research and development | | 32,805 | | 108,510 | | 91,879 | |||
| General and administrative | | 26,530 | | 27,779 | | 30,257 | |||
| Restructuring | | | 5,565 | | | — | | | — |
| Total operating expenses | | 65,520 | | 142,463 | | 129,402 | |||
| Operating loss | | (58,383) | | (121,495) | | (87,535) | |||
| Other income, net | | 2,828 | | 3,586 | | | 2,061 | ||
| Impairment of long-lived assets | | | (4,274) | | | — | | | — |
| Inventory write-down | | | (2,963) | | | — | | | — |
| Non-cash interest expense on liability related to sales of future royalties and milestones | | | (8,473) | | | (604) | | | — |
| Loss before benefit from income taxes | | | (71,265) | | | (118,513) | | | (85,474) |
| Benefit from income taxes | | | 398 | | | — | | | — |
| Net loss | | $(70,867) | | $(118,513) | | $(85,474) | |||
| Net loss per share: | | | | ||||||
| Basic and Diluted | | $(15.53) | | $(26.26) | | $(19.12) | |||
| Weighted average shares: | | | | | | ||||
| Basic and Diluted | | 4,562,738 | | 4,512,422 | | 4,471,130 | |||
| Other comprehensive income (loss), net of tax of $0: | | | | ||||||
| Change in unrealized gains (losses) on available-for-sale marketable securities | | 260 | | 1,412 | | (1,314) | |||
| Total comprehensive loss | | $(70,607) | | $(117,101) | | $(86,788) | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.